–Two-Year Follow-up Results Confirm Significant Efficacy and No Serious Adverse Events in Patients Using the StemSpine® Procedure for the Treatment of Chronic Low Back Pain —
PHOENIX, March 23, 2022 /PRNewswire/ — Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a leading commercial-stage biotechnology company focused on a regenerative approach to immunotherapy, of Urology, Neurology and Orthopedics, today announced positive two-year follow-up data for the company’s StemSpine® pilot study, demonstrating the significant efficacy of the StemSpine® procedure for the treatment of chronic low back pain with no serious adverse effects reported.
StemSpine® is a patented procedure that uses bone marrow aspiration from the patient for the treatment of chronic lower back pain.
There were no safety issues for up to two years and the StemSpine® procedure resulted in an 87% efficacy rate in treated patients. The Society plans to submit a manuscript for publication in a peer-reviewed journal and present the data at future orthopedic and sports medicine conferences.
“The positive two-year data from our StemSpine® pilot study is very encouraging, and we are excited to engage with practitioners on commercialization,” said Timothy Warbington, President and Chief Executive Officer of the Company. “To our knowledge, this pilot project is the first demonstration of the clinical effectiveness of injecting bone marrow aspirate into the areas surrounding the disc, thereby repairing, remodeling and improving blood supply around the disc and the lower back region. We believe StemSpine® represents an attractive non-surgical option for many of the millions of Americans who experience non-surgical chronic low back pain.”
Sahil NockChief Commercial Officer of the Company, added, “Given the timely receipt of this important and supportive data, I look forward to accelerating our StemSpine® program by introducing it to the physician community at the annual StemSpine® conference. the American Academy of Orthopedic Surgeons which takes place in Chicago this week, March 22-26. Building strong advisory boards with notable KOLs has been a mainstay of my career, and I’m excited to leverage my experience to accelerate our efforts to translate the StemSpine® procedure. »
The Society plans to hold a series of one-on-one meetings with physicians throughout the conference. please contact Sahil Nock using the information found at the end of this press release if you wish to connect. We can also be contacted through our website at www.StemSpine.com.
About Creative Medical Technology Holdings
Creative Medical Technology Holdings, Inc. is a commercial-stage biotechnology company specializing in stem cell technology in the fields of immunotherapy, urology, neurology and orthopedics. For more information about the company, please visit www.creativemedicaltechnology.com.
This press release may contain forward-looking statements, including, but not limited to, comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements relate to future events and conditions and, therefore, involve risks and uncertainties. Actual results may differ materially from those currently anticipated in these statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission’s website at www.sec.gov.
View original content for multimedia download: https://www.prnewswire.com/news-releases/creative-medical-technology-announces-positive-top-line-results-for-stemspine-pilot-study-301508295.html
SOURCE Creative Medical Technology Holdings, Inc.